
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.

Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
The yin/yang of inflammatory status: Blood-brain barrier regulation during sleep. VER MÁS
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile....
Fecha de publicación: 20 de marzo del 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear...
Fecha de publicación: 10 de abril de 2019 CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with...
Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNFα using flow cytometry detection....
Regulatory Pathway for Licensing Biotherapeutics in Mexico. VER MÁS
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. VER MÁS

+52 (55) 5729 6000 Ext. 62543
Escuela Nacional de Ciencias Biológicas. Prolongación de Carpio y Plan de Ayala S/N, Del. Miguel Hidalgo, CDMX, C.P. 11340.
©2026 UDIBI